The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...

Q3 2025 Earnings Call Transcript November 4, 2025 Corcept Therapeutics Incorporated misses on earnings expectations. Reported ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate ...

NNVC READ THE FULL NNVC RESEARCH REPORT Business Update Mpox Trial to Initiate in Late 2025/Early 2026 NanoViricides, Inc. (NYSE:NNVC) is planning to initiate a Phase 2 clinical trial for the ...

Q3 2025 Earnings Call Transcript November 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1 ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ...

Psyence Biomedical Ltd. ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a ...